Cara Cassino, speaking at Late Phase Drug Development World Europe 2011

Cara Cassino,
Vice President, Medicines Development Group
Pfizer

Dr. Cassino is Vice President of the Medicines Development Group for Pulmonary Vascular Disease (PVD) and Rare Diseases at Pfizer Inc. in NY. In this capacity, she leads a global team responsible for worldwide clinical development and medical affairs activities, guiding the strategic vision for drug development in PVD and Rare Diseases.

Dr Cassino is a board certified pulmonologist who completed her medical training at New York University (NYU) School and Mount Sinai Schools of Medicine in New York City. After completing her fellowship in 1994, she held a full time faculty position as Assistant Professor of Medicine in the Division of Pulmonary and Critical Care Medicine at NYU School of Medicine. There she served as Medical Director of the Bellevue Hospital Chest and Asthma Clinics, while pursuing clinical research interests in airways disease and severe asthma.

In 2001, Dr Cassino joined Boehringer Ingelheim Pharmaceuticals, based in Ridgefield Connecticut, where she was responsible for the design, conduct and analysis Phase II-IV clinical trials in COPD. During her tenure at Boehringer Ingelheim, Dr Cassino held positions of increasing responsibility, ultimately serving as Executive Director of US Respiratory Medical Affairs. In 2008 Dr Cassino joined Pfizer Inc. as Global Medical Team Lead for Antibacterials. Shortly thereafter she assumed the role of VP for Clinical Development and Medical Affairs for Pulmonary Vascular Disease. She has published broadly on topics related to the treatment on asthma and COPD and has maintained her academic affiliation at NYU School of Medicine.

Appearing:

Day One- Wednesday 7th December 2011

11.30am

CASE STUDY: Late phase study design in paediatrics medicine– Looking at Revatio, a treatment for Pulmonary Arterial Hypertension

• Addressing the challenges US and EU paediatric data requirements – moving towards globalized paediatric programs
• Extrapolating from adult clinical data to limiting paediatric clinical trial exposure
• Use of modeling to address data gaps and support age appropriate endpoints for paediatric trials

Cara Cassino,

Vice President, Medicines Development Group,
Pfizer

Sponsor Late Phase Drug Development World Europe 2011 ›

Premium sponsor